pharma · Primary Mitochondrial Myopathy · Advanced Solid Tumors, Advanced Breast Cancer · OKUR
OnKure Therapeutics
OnKure Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker OKUR. Primary therapeutic focus areas include Primary Mitochondrial Myopathy, Advanced Solid Tumors, Advanced Bre
Boulder, USA HQ
2011 Founded
42 Employees
Public company Type
OKUR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2011
- Employees
- 42
- Programs
- 8
- Drugs
- 4
- Patents
- 7
OKI-219-101
Phase 1 · other · Advanced Solid Tumors, Advanced Breast Cancer
OKI-219-101 for Advanced Solid Tumors, Advanced Breast Cancer is a Phase 1 program (other) at OnKure Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code OKI-219-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- OnKure Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced Solid Tumors, Advanced Breast Cancer
- Status
- active
- Trials
- 1